Development and validation of novel enzyme activity methods to assess inhibition of matrix metalloproteinases (MMPs) in human serum by antibodies against enzyme therapeutics

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 408-414

  Edkins, Thomas J ^a   Alhadeff, Jack A ^b   Kwok, Vincent ^c   Kalensky, Charles ^c   Rock, Marie T ^c   Vidmar, Thomas J ^d   Del Tito, Benjamin J ^e  

^a Edkins Pharma Services LLC   (United States)

^b Protein Therapeutics Consulting   (United States)

^c WIL Research   (United States)

^d Biostat Consultants Inc   (United States)

^e Auxilium Pharmaceuticals Inc   (United States)

Author keywords

Cross reactivity of anti drug antibodies; Enzyme therapeutics; Matrix metalloproteinases; MMP enzyme activity inhibition assay method development and validation

Indexed keywords

ANTIBODY; COLLAGENASE 3; GELATINASE A; ICE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN;

ACCURACY; ARTICLE; ASSAY; CLOSTRIDIUM HISTOLYTICUM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SUBSTRATE; ENZYME THERAPY; HUMAN; METHODOLOGY; PH; PRIORITY JOURNAL; ROOM TEMPERATURE; VALIDATION STUDY;

ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BIOLOGICAL ASSAY; CALIBRATION; CLOSTRIDIUM HISTOLYTICUM; CROSS REACTIONS; ENZYME STABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MICROBIAL COLLAGENASE; RECOMBINANT PROTEINS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TEMPERATURE; TIME FACTORS;

EID: 84866256455     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.06.012     Document Type: Article

References (24)

1. Vellard M. The enzyme as drug: application of enzymes as pharmaceuticals. Curr. Opin. Biotech. 2003, 14:1-7.
2. Wier H.A., Kuhn R.J. Pancreatic enzyme supplementation. Curr. Opin. Pediatr. 2011, 23:541-544.
3. Wang J., Lozier J., Johnson G., Kirschner S., Verthelyi D., Pariser A., Shores E., Rosenberg A. Neutralziing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nature Biotech. 2008, 26:901-908.
4. (accessed 23 February 2012). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
5. (accessed 23 February 2012). http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/002048/human_med_001423.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d124.
6. Starkweather K.D., Lattuga S., Hurst L.C., Badlamente M.A., Guilak F., Sampson S.P., Dowd A., Wisch A. Collagenase in the treatment of Dupuytren's disease: an in vitro study. J. Hand Surg. 1996, 21A:490-495.
7. Smith A.C. Diagnosis and indications for surgical treatment. Hand Clinics 1991, 7:635-642.
8. Hurst L.C., Badlamente M., Hentz V.R., Hotchkiss R.N., Kaplan T.D., Meals R.A., Smith T.D., Rodzvilla J.R. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N. Engl. J. Med. 2009, 361:968-979.
9. Butler G.S., Overall C.M. Updated biological roles for matrix metalloproteinases and new " intracellular" substrates revealed by degradomics. Biochemistry 2009, 48:10830-10845.
10. Cauwe B., Van den Steen P.E., Opdenakker G. The biochemical, biological kaleidoscope of cell surface substrates processed by matrix metalloproteineases. Crit. Rev. Biochem. Mol. Biol. 2007, 42:113-185.
11. Edkins T.J., Koller-Eichorn R., Alhadeff J.A., Mayer U., Faust H., Del Tito B. Assessment of potential cross-reactivity of human endogenous matrix metalloproteinases (MMPs) with collagenase Clostridium histolyticum (CCH) antibodies in human sera obtained from patients with Dupuytren's contracture. Clin. Vaccine Immunol. 2012, 19:562-569.
12. Kirschner S. A regulatory perspective on immunogenicity surveillance considerations in the post-approval phase of biotherapeutics. AAPS Biotechnology Conference 2010.
13. European Medicines Agency, 2007. Doc. Ref. 520 EMEA/CHMP/BMWP/14327/2006.
14. U.S. Department of Health and Human Services, Food and Drug Administration, 2009. (Draft) Guidance for Industry. Assay development for immunogenicity testing of therapeutic proteins.
15. Macpherson L.J., Bayburt E.K., Caparelli M.P., Carroll B.J., Goldstein R., Justice M.R., Zhu L., Hu S., Melton R.A., Fryer L., Goldberg R.L., Doughty J.R., Spirito S., Blancuzzi V., Wilson D., O'Byrne E.M., Ganu V., Parker D.T. Discovery of CGS 27023A, a non-peptidic potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 2525-2532.
16. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267-1281.
17. Ana Spec Sensolyte® 520 MMP Assay Kits, AnaSpec, Inc., (accessed 8 March 2012). http://www.anaspec.com/products/productcategory.asp?id=328.
18. Enzo Life Science Inhibitor Profiling Kit, BML-AK016 Instruction Manual, (accessed 25 February 2012). http://static.enzolifesciences.com/fileadmin/enzo/BML/ak016.pdf.
19. Reversible inhibition and activation. Fundamentals of Enzyme Kinetics 2004, 140-141. Butterworths, London. third ed. A. Cornish-Bowden (Ed.).
20. Midwest BioResearch, LLC, Validation of an enzyme activity assay procedure for determination of inhibition of matrix metalloproteinase 1 (MMP-1) activity in human serum, MBR10-381 (2010).
21. Midwest BioResearch, LLC, Validation of an enzyme activity assay procedure for determination of inhibition of matrix metalloproteinase 2 (MMP-2) activity in human serum, MBR10-178 (2010).
22. Midwest BioResearch, LLC, Validation of an enzyme activity assay procedure for determination of inhibition of matrix metalloproteinase 3 (MMP-3) activity in human serum, MBR10-382 (2010).
23. Midwest BioResearch, LLC, Validation of an enzyme activity assay procedure for determination of inhibition of matrix metalloproteinase 8 (MMP-8) activity in human serum, MBR10-383 (2010).
24. Midwest BioResearch, LLC, Validation of an enzyme activity assay procedure for determination of inhibition of matrix metalloproteinase 13 (MMP-13) activity in human serum, MBR10-368 (2010).